ResearcherThe University of SydneyNo recent work listed
Sohel M. Julovi
Matched on ORCID iD 0000-0003-0834-2366; OpenAlex author ID A5080031908. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 2 papers
Papers 4
- Biomimetic Gemcitabine-Lipid Prodrug Nanoparticles for Pancreatic Cancer. Co-author DOI 10.1002/cplu.202000253↗
- Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein A-II and a lipid gemcitabine prodrug in … Co-author DOI 10.1016/j.canlet.2020.08.045↗
- Apolipoprotein A-II Plus Lipid Emulsion Enhance Cell Growth via SR-B1 and Target Pancreatic Cancer In Vitro and In Vivo. Co-author DOI 10.1371/journal.pone.0151475↗
- Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-13-3377↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Aiqun Xue · 4 shared papers, 2014–2020 · strength 0.32
- Paper Biomimetic Gemcitabine-Lipid Prodrug Nanoparticles for Pancreatic Cancer. DOI 10.1002/cplu.202000253↗
- Paper Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein … DOI 10.1016/j.canlet.2020.08.045↗
- Paper Apolipoprotein A-II Plus Lipid Emulsion Enhance Cell Growth via SR-B1 and Target Pancreatic Cancer In Vitro and In Vivo. DOI 10.1371/journal.pone.0151475↗
- Ross C. Smith · 4 shared papers, 2014–2020 · strength 0.32
- Paper Biomimetic Gemcitabine-Lipid Prodrug Nanoparticles for Pancreatic Cancer. DOI 10.1002/cplu.202000253↗
- Paper Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein … DOI 10.1016/j.canlet.2020.08.045↗
- Paper Apolipoprotein A-II Plus Lipid Emulsion Enhance Cell Growth via SR-B1 and Target Pancreatic Cancer In Vitro and In Vivo. DOI 10.1371/journal.pone.0151475↗
- Jerikho C. Bulanadi · 3 shared papers, 2016–2020 · strength 0.28
- Paper Biomimetic Gemcitabine-Lipid Prodrug Nanoparticles for Pancreatic Cancer. DOI 10.1002/cplu.202000253↗
- Paper Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein … DOI 10.1016/j.canlet.2020.08.045↗
- Paper Apolipoprotein A-II Plus Lipid Emulsion Enhance Cell Growth via SR-B1 and Target Pancreatic Cancer In Vitro and In Vivo. DOI 10.1371/journal.pone.0151475↗
- Minoo J. Moghaddam · 3 shared papers, 2016–2020 · strength 0.28
- Paper Biomimetic Gemcitabine-Lipid Prodrug Nanoparticles for Pancreatic Cancer. DOI 10.1002/cplu.202000253↗
- Paper Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein … DOI 10.1016/j.canlet.2020.08.045↗
- Paper Apolipoprotein A-II Plus Lipid Emulsion Enhance Cell Growth via SR-B1 and Target Pancreatic Cancer In Vitro and In Vivo. DOI 10.1371/journal.pone.0151475↗
- Anthony James Gill · 3 shared papers, 2014–2020 · strength 0.20
- Paper Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein … DOI 10.1016/j.canlet.2020.08.045↗
- Paper Apolipoprotein A-II Plus Lipid Emulsion Enhance Cell Growth via SR-B1 and Target Pancreatic Cancer In Vitro and In Vivo. DOI 10.1371/journal.pone.0151475↗
- Paper Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal a… DOI 10.1158/1078-0432.ccr-13-3377↗
- Jaswinder Singh Samra · 1 shared paper, 2014 · strength 0.04
- Nick Pavlakis · 1 shared paper, 2014 · strength 0.04
- Matthew H. Wong · 1 shared paper, 2014 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.